Immunologic Signatures Following Surgery for Pancreatic Cancer

The goal of this pilot study is to evaluate and describe the immunologic and overall outcomes
of subjects who undergo routine pancreatectomy with or without irreversible electroporation
(IRE) for pancreatic cancer. Immunologic markers in the blood will be measured at several
time points before and after surgery to determine if surgical approach is associated with
different immunologic responses. Secondary outcomes will include mortality and morbidity;
operative time; blood loss and transfusion requirements; and oncologic outcomes such as:
margin status, lymph node harvest, disease-free survival, and overall survival. Analysis of
immune response will help the investigator determine whether to expand the pilot into a
larger study.